Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
Director departure
INFINITY PHARMACEUTICALS, INC. (INFI) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/29/2023 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
07/25/2023 8-K Quarterly results
07/24/2023 8-K Quarterly results
07/14/2023 8-K Quarterly results
07/03/2023 8-K Quarterly results
06/30/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/28/2023 8-K Quarterly results
02/23/2023 8-K Acquisition/merger/asset purchase announced
12/30/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update – MARIO-3 Update in Patients with 1L TNBC showing 52% increase in one-year progression free survival rate in ITT patient population compared to Impassion130 benchmark –"
08/25/2022 8-K Other Events  Interactive Data
08/09/2022 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update – Positive eganelisib data from two-year landmark analysis demonstrate durable survival benefit in urothelial cancer patients from MARIO-275 –"
06/16/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
03/29/2022 8-K Quarterly results, Appointed a new director
Docs: "AMENDMENT NO. 1 TO 2019 EQUITY INCENTIVE PLAN OF INFINITY PHARMACEUTICALS, INC.",
"Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights – MARIO-4, the first eganelisib registration-enabling trial, in front-line metastatic triple negative breast cancer expected to initiate by the end of 2022 –"
01/05/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance - MARIO-4 registration study in frontline metastatic triple negative breast cancer to be initiated by year end 2022 -"
12/10/2021 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update – Encouraging data for eganelisib in both PD-L1 and PD-L1 mTNBC patients, with meaningful prolongation of PFS over IMpassion130 reference benchmark –"
09/07/2021 8-K Quarterly results
07/27/2021 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Company Update",
"9 2L UC MARIO-2751 1L TNBC MARIO-32",
"Infinity Pharmaceuticals Presents Updated Data from Phase 2 MARIO-275 Trial in Urothelial Cancer and Phase 2 MARIO-3 Trial in Triple Negative Breast Cancer"
06/11/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/06/2021 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Infinity Pharmaceuticals Provides Update for Eganelisib in Patients with Metastatic Urothelial Cancer"
12/09/2020 8-K Investor presentation
Docs: "0 20 40 60 80 100",
"Infinity Pharmaceuticals Presents Front-Line Triple Negative Breast Cancer Data from Ongoing Phase 2 MARIO-3 Trial at the 2020 San Antonio Breast Cancer Symposium"
11/09/2020 8-K Quarterly results
Docs: "Infinity Pharmaceuticals Provides Company Update and Third Quarter 2020 Financial Results – MARIO-275 IDMC Determined that Risk/Benefit for Patients Warrants Resumption of Enrollment&#59; Infinity to Determine Next Steps by Year End –",
"Infinity Pharmaceuticals Presents New MARIO-1 Phase 1/1b Clinical Data at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting"
09/29/2020 8-K Quarterly results
08/25/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/02/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy